We can find that the pursuit of standardized diagnostic criteria for migraine, exploration of CGRP and its receptor mechanisms in migraine pathogenesis, and evaluation of CGRP receptor antagonists and monoclonal antibodies for migraine treatment efficacy and safety emerge as predominant focal points in the field. This evidence concerns the gene CALCA and migraine disorder.